1Stewart AF, Horst R, Deftos LJ, et al. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med, 1980,303 : 1377-1383.
2Mundy GR, lbbotson K J, DSouza SM, et al. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med, 1984, 310:1718-1727.
3Fisken RA, Heath DA, Bold AM. Hypercalcemia: a hospital survey. O J Med,1980,49:405-418.
4Blomqvist CP. Malignant hypercalcemia: a hospital survey. Acta Med Scand, 1986,220:455-463.
5Burt ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg, 1980,115:704-707.
6Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol,2001,19:558-567.
7Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy-Drugs, 2003,63:417-437.
8Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002,29(6 Suppl 21):12-18.
3Arai Y C, Matsubara T, Shimo K, et al. Low- dcse gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low - dose imipramine [ J ]. J Anesth, 2010, 24(3): 407.
4Bolzoni M,Storti P,Bonomini S,et al.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules[J].Exp Hematol,2012,41(4):387-397.
5Costa L,Lipton A,Hadji P,et al.Treatment of bone metastases before the onset of pain[J].Int J Clin Oncol,2013,18(3):531-538.
6Rogers TL,Holen I.Tumor macrophages as potential targets of bisphosphonates[J].J Transl Med,2011,17(9):177.
